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Abstract
Background: With regards to the importance of traumatic brain injury (TBI) and its high incidence rate in Iran as well as its severe
consequences, it is important to determine the safety and efficiency of modafinil to increase the level of consciousness in hospital-
ized TBI patients.
Methods: This double-blind randomized controlled trial was done during year 2016. Sixty patients with TBI and moderate GCS score
between 9 and 13 had the inclusion criteria and entered the study and were divided to two groups. Patients in the treatment group
received 200 mg of modafinil once a day and the control group received the placebo. Overall, 24 hours after admission, defined as
base day, modafinil was prescribed for 196 hours after admission and GCS scores were recorded and this period was defined as the
last day. Level of consciousness in both treatment and control groups was assessed by the GCS score. Data were analyzed by the SPSS
version 21 software using the independent t-test with intention-to-treat approach.
Results: Among 60 patients, there were 34 (56.66%) males and 26 (43%) females; 45 (75%) survived. The ITT analysis was employed to
investigate changes in the level of consciousness (LOC) after prescribing modafinil and placebo. Based on the findings, modafinil
prescription was not associated with significant differences in LoC in the first time period (24 hours after) and the last day (196
hours) (P > 0.05).
Conclusions: Prescribing modafinil was not associated with significant changes in LoC in comparison with the placebo.
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1. Background
Traumatic brain injury (TBI) is a common problem (1).
The world health organization report stated that the TBI
burden will rise above other diseases by 2020, and will be-
come a major cause of morbidity and mortality (2). Fur-
thermore, TBI is a major cause of death in patients 45 years
old and older; almost 40% of all deaths in the United States
of America are attributed to TBI (3-5). It has been estimated
that the annual cost of TBIs in the USA is about 56.2 bil-
lion dollars (6). Injuries that are related to road traffic acci-
dents, falls, and violence are the most important causes of
TBIs (6). Annual costs of TBIs in the US are about 56.3 billion
dollars (7).
In Iran, TBIs are the second leading cause of death in
different age groups, following cardiovascular diseases. Af-
ter age adjustment, it is the first leading cause of death in
under 40-year-olds. In Iran, each year about 27000 people
die because of road traffic accidents (8). Furthermore, pre-
cise data on TBIs are not available in Iran, yet a recently con-
ducted study on this issue has shown that most of the vic-
tims are young, with an average age of 34.7 years old; it was
also revealed that TBIs account for 53.5% of deaths due to
road traffic accidents. Most of them were head injuries and
were hospitalized (9).
About two-thirds of TBI victims develop neurological
complications, which can last for decades (10, 11). In ad-
dition, it causes behavioral and mood problems, memory
impairment, and operational functions that are difficult
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to treat (12). Common symptoms are excessive daytime
sleepiness and fatigue, which can significantly reduce the
quality of life and daily operations, such as work and so-
cial activities (13). Different parameters are used in neu-
rological examination of TBI patients; one of them is the
level of consciousness (LoC). The glasgow coma scale (GCS)
has been widely accepted as the standard assessment in-
strument for TBI (14). The GCS is a scientific instrument for
monitoring LoC changes based on the best physical, verbal,
and visual responses. A low GCS status is an indicator of
an increased risk of an intracranial lesion, and is an impor-
tant factor indicating the necessity for surgery to remove
the hematoma (15). Furthermore, GSC is the most impor-
tant factor in prognosis and outcome of patients with TBIs.
Also, professionals use the GCS before using CT-scan to de-
termine, which patients require contrast studies to diag-
nose bleeding. It has been proven that there is a strong as-
sociation between glasgow coma and risk of hematoma in-
side the skull (16, 17).
The prognosis can be determined based on the GCS.
However, it has shortcomings, for instance, patients, who
are in a coma have an endotracheal tube in their trachea
that prevents verbal assessment. The FOUR criteria is a new
scale that has been developed with GCS’s shortcomings in
mind and can be useful for ICU patients. This new scale
contains novel neurological-clinical findings that are ap-
plicable in patients with consciousness disorders. The ex-
act examination of the LoC is one of the main challenges
of clinical care, and for this reason, having a scale to exam-
ine the LoC is crucial, so that the clinical team constantly
monitors LoC changes. Based on what was mentioned be-
fore, an exact and applicable criterion, which can be used
by physicians and nurses is needed. The FOUR criteria have
advantages that can be used alongside the CGS (18, 19).
Modafinil is a new awakening drug that is different from
amphetamine and methylphenidate, and is also known as
the classical psychic stimulus. Its exact mechanism is not
yet known yet probably works through the effect on both
the noradrenergic and dopaminergic systems and inter-
action with hypocretin/orexin, which induces awakening
(20). Initially, it was approved by the food and drug ad-
ministration for patients with extreme daytime sleepiness
(EDS). In 5% of cases it causes anorexia and increased con-
sciousness (21). Until now, various studies have been con-
ducted on the use of this drug to treat EDS and LoC in pa-
tients with a diagnosis of HIV, lung cancer, stroke, primary
biliary cirrhosis, and LoC due to TBIs (5, 22-25).
2. Objectives
The current study aimed at investigating the impact of
modafinil on LoC in patients with TBIs of moderate sever-
ity, hospitalized at the intensive care unit (ICU) of the re-
searcher’s, during year 2016.
3. Methods
This double-blind randomized controlled clinical trial
was done in 2016 on hospitalized ICU patients. The study
population consisted of all volunteer TBI patients that had
undergone surgery and were between 18 and 65 years old
with normal GCS score (9 to 13) during the admission time.
FOUR score was also assessed at the time of admission.
Patients with history of severe hypersensitivity to
modafinil, angina pectoris, myocardial ischemia, left ven-
tricular hypertrophy, and mitral valve prolapse, for whom
Modafinil could have side effects (26, 27), were excluded.
Overall, 60 patients had the inclusion criteria and were
entered in the study. Patients were randomized to two
groups using a random numbers table, using their chart
ID. Each group consisted of 30 patients.
To ensure the safety and efficiency of modafinil, 200
mg of modafinil was prescribed for the treatment group
and the researchers assessed the initial outcomes in the
first 24 hours after admission using the GCS score.
Patients in the treatment group received 200 mg of
modafinil once a day and the control group received the
placebo. Twenty-four hours after admission was defined as
base day, and modafinil was prescribed 196 hours after ad-
mission and GCS scores were recorded, and this period was
defined as the last day.
Ethical committee of the university approved the study
and initial written consent was obtained from the patient’s
family at the randomization stage.
Level of consciousness in both treatment and control
groups was assessed by the GCS score. Overall, 15 patients
died at the end of the study period. Data were analyzed by
SPSS version 21 using the independent t-test with intention-
to-treat approach.
4. Results
Based on the findings of the current study, the patients
were mostly male (56.66%), between 51 and 60 kg (50%), and
55% were in BMI category of 18.5 to 24.9. Furthermore, 75%
were hospitalized because of traffic-accidents. Thirty-six
patients had systolic blood pressure of 101 to 110. The av-
erage blood pressure in patients in the group of 81 to 90
(mm Hg) in 45 (75%) was the most frequent. Out of 60 par-
ticipants, 45 (75%) survived (Table 1).
At time of admission, based on the findings, Mean
FOUR score was 10.67. Its average in males and females was
10.54 and 10.89, respectively. The mean GCS score at the
time of admission was 10.95 (Table 2).
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Table 1. Demographic Characteristics of Patients
Variable Frequency Percentage (%)
Age (years old)
18 - 40 15 25
41 - 50 40 66.66





Less than 50 3 5
51 to 65 30 50
66 to 80 12 20
More than 80 15 25
BMI
18.5 to 24.9 33 55
25 to 29.9 12 20
30 to 34.9 12 20
35 and higher 3 5
Cause of injury
Traffic accident 45 75
Fall 12 20
Others 3 About 5
Systolic blood pressure (mm HG)
Less than 90 3 5
90 to 100 9 15
101 to 110 36 60
111 to 120 9 15
More than 120 3 5
MAP (mm HG)
Less than 70 3 5
70 to 80 6 10
81 to 90 6 10




Daily changes of level of consciousness according
to GCS score in different time periods after prescribing
modafinil showed that modafinil administration was not
associated with significant differences at the base day (24
hours after admission/base) and the last day (196 hours af-
Table 2. Level of Consciousness at the Admission Time
Indicator Mean SD Median
FOUR
Male 10.54 0.38 11
Female 10.89 0.2 11
Total 10.67 0.29 11
GCS
Male 10.71 0.25 10
Female 11.9 0.41 10
Total 10.95 0.36 11
ter admission) (P > 0.05) (Table 3).
5. Discussion
Galvin and colleagues (2010) estimated that verbal
score after prescribing modafinil and placebo was 3 ± 1.2
and 3.8±2.5, respectively. By considering a 95% confidence
interval and a power equal to 99%, sample size for each
group in the current study was 30. Variables were as fol-
lows: gender, age, cause of injury, prognosis, systolic blood
pressure, MAP, BMI, GCS, and FOUR score.
The current study used the intention-to-treat ap-
proach to examine daily changes of LoC after prescribing
modafinil or placebo at different time periods. No sig-
nificant differences were found between treatment and
control groups in terms of LoC at the first time period
(base) and the last day.
Jha and Colleagues (25) investigated the impact of
modafinil on fatigue and sleepiness in patients with TBIs;
53 patients with TBIs randomly received 400 mg modafinil
or equal amounts of placebo. Primary outcomes for fatigue
measured the severity of fatigue and sleep. The findings
showed that there was no statistical difference between
modafinil and placebo in terms of durational effects and
basic scores in fatigue severity at the fourth or tenth week.
In terms of daily sleepiness, no significant change was ob-
served between modafinil and placebo. In another study,
Stankoff et al. (28) examined the impact of modafinil in
patients with MS. They examined 115 patients, which were
divided to two groups: 56 patients treated with modafinil
and 56 with placebo. They found that there was no statis-
tical difference between the two groups and no improve-
ment in patients receiving modafinil (27). Kaiser and Col-
leagues also examined the impact of modafinil on sleepi-
ness and fatigue. They divided 20 patients to two groups,
intervention and control. Their study revealed a signifi-
cant impact on severe fatigue in the intervention group,
yet it did not have an impact on fatigue after the accident
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Table 3. Level of Consciousness According to GCS Score at Base Day and Last Day
Base Day (24 h After Admission) Last Day (196 h After Admission) Independent Samples
T-Test
P Value
Modafinil M(SD) Placebo M(SD) Modafinil M(SD) Placebo M(SD)
GCS score in patients
with moderate coma
11.1 (0.23) 11.26 (0.48) 13 (0.18) 12.85 (0.56) 1.826 0.144
(5). Ondo et al. (29), in a study on patients with parkinson,
found that modafinil had a significant impact on severe
sleepiness. Different studies showed that modafinil had ef-
fects on fatigue, for instance, Rammohan et al. (30) showed
that it had positive effects on patients with MS.
Furthermore, TBIs caused serious changes in the LoC
and assessment was difficult. The ability to respond to
internal and external stimuli was affected. Rezaee et al.
found that the average score in the FOUR criteria before
and after the intervention had a significant difference, yet
no difference was found in GCS (31, 32). Some studies com-
pared GCS and FOUR criteria system, and most of them
mentioned the latter to be a better scale.
5.1. Conclusions
Findings of the current study showed that modafinil
does not significantly affect LoC.
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